These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 21317460)

  • 1. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.
    Zlobec I; Lugli A
    Oncotarget; 2010 Nov; 1(7):651-61. PubMed ID: 21317460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.
    Zlobec I; Lugli A
    World J Gastroenterol; 2009 Dec; 15(47):5898-906. PubMed ID: 20014453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour budding in colorectal cancer: what do we know and what can we do?
    De Smedt L; Palmans S; Sagaert X
    Virchows Arch; 2016 Apr; 468(4):397-408. PubMed ID: 26613731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
    Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
    J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor budding in colorectal cancer--ready for diagnostic practice?
    Koelzer VH; Zlobec I; Lugli A
    Hum Pathol; 2016 Jan; 47(1):4-19. PubMed ID: 26476568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and pathogenetic aspects of tumor budding in colorectal cancer.
    Dawson H; Lugli A
    Front Med (Lausanne); 2015; 2():11. PubMed ID: 25806371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma.
    Konishi Y; Kawamata F; Nishihara H; Homma S; Kato Y; Tsuda M; Kohsaka S; Einama T; Liu C; Yoshida T; Nagatsu A; Tanino M; Tanaka S; Kawamura H; Kamiyama T; Taketomi A
    Med Oncol; 2018 Jun; 35(7):104. PubMed ID: 29892782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
    Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
    Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
    Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review.
    Cao H; Xu E; Liu H; Wan L; Lai M
    Pathol Res Pract; 2015 Aug; 211(8):557-69. PubMed ID: 26092594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy.
    Bhangu A; Wood G; Mirnezami A; Darzi A; Tekkis P; Goldin R
    Surg Oncol; 2012 Dec; 21(4):316-23. PubMed ID: 22981546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-mesenchymal transition‑associated microRNAs in colorectal cancer and drug-targeted therapies (Review).
    Jin D; Fang Y; Li Z; Chen Z; Xiang J
    Oncol Rep; 2015 Feb; 33(2):515-25. PubMed ID: 25435189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
    Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
    Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor budding in colorectal carcinoma: time to take notice.
    Mitrovic B; Schaeffer DF; Riddell RH; Kirsch R
    Mod Pathol; 2012 Oct; 25(10):1315-25. PubMed ID: 22790014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial-mesenchymal transition and colorectal cancer aggressiveness.
    Franke FC; Slusarenko BO; Engleitner T; Johannes W; Laschinger M; Rad R; Nitsche U; Janssen KP
    Int J Cancer; 2020 Sep; 147(6):1715-1731. PubMed ID: 32147820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    De Smedt L; Palmans S; Andel D; Govaere O; Boeckx B; Smeets D; Galle E; Wouters J; Barras D; Suffiotti M; Dekervel J; Tousseyn T; De Hertogh G; Prenen H; Tejpar S; Lambrechts D; Sagaert X
    Br J Cancer; 2017 Jan; 116(1):58-65. PubMed ID: 27884016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer.
    Zhang N; Ng AS; Cai S; Li Q; Yang L; Kerr D
    Lancet Oncol; 2021 Aug; 22(8):e358-e368. PubMed ID: 34339656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and diagnostic significance of tumor budding associated with β-catenin expression in submucosal invasive colorectal carcinoma.
    Umemura K; Takagi S; Shimada T; Masuda T; Shiga H; Takahashi S; Takahashi S; Kinouchi Y; Shibuya D; Shimosegawa T
    Tohoku J Exp Med; 2013 Jan; 229(1):53-9. PubMed ID: 23238650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.